NVCR NOVOCURE LTD revenue, earnings and financials

For the quarter ended June 30, 2026, NOVOCURE LTD reported revenue of $184M (up 15.6% from a year earlier), net income of −$15.7M and diluted EPS of −$0.13; over the last four quarters revenue was $699M and net income −$149M; for the fiscal year ended December 2025 revenue was $655M, up 8.3% on the year before.

NVCR annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $655M, gross profit $488M, operating income −$154M, net income −$136M (margin -20.8%), EPS −$1.22
• Fiscal year ended Dec 2024: revenue $605M, gross profit $468M, operating income −$170M, net income −$169M (margin -27.9%), EPS −$1.56
• Fiscal year ended Dec 2023: revenue $509M, gross profit $381M, operating income −$233M, net income −$207M (margin -40.6%), EPS −$1.95
• Fiscal year ended Dec 2022: revenue $538M, gross profit $423M, operating income −$89.5M, net income −$93.0M (margin -17.3%), EPS −$0.88
• Fiscal year ended Dec 2021: revenue $535M, gross profit $420M, operating income −$44.3M, net income −$58.0M (margin -10.8%), EPS −$0.56

NVCR quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $184M (up 15.6% year over year), net income −$15.7M, EPS −$0.13
• Quarter ended Mar 31, 2026: revenue $174M (up 12.3% year over year), net income −$71.1M, EPS −$0.62
• Quarter ended Dec 31, 2025 (from the annual report): revenue $174M (up 8.1% year over year), net income −$24.5M, EPS −$0.22
• Quarter ended Sep 30, 2025: revenue $167M (up 7.8% year over year), net income −$37.3M, EPS −$0.33
• Quarter ended Jun 30, 2025: revenue $159M (up 5.6% year over year), net income −$40.1M, EPS −$0.36
• Quarter ended Mar 31, 2025: revenue $155M (up 11.9% year over year), net income −$34.3M, EPS −$0.31
• Quarter ended Dec 31, 2024 (from the annual report): revenue $161M (up 20.5% year over year), net income −$66.3M, EPS −$0.61
• Quarter ended Sep 30, 2024: revenue $155M (up 21.8% year over year), net income −$30.6M, EPS −$0.28
• Quarter ended Jun 30, 2024: revenue $150M (up 19.3% year over year), net income −$33.4M, EPS −$0.31
• Quarter ended Mar 31, 2024: revenue $139M (up 13.4% year over year), net income −$38.8M, EPS −$0.36
• Quarter ended Dec 31, 2023 (from the annual report): revenue $134M (up 4.2% year over year), net income −$47.0M, EPS −$0.45
• Quarter ended Sep 30, 2023: revenue $127M (down 2.8% year over year), net income −$49.5M, EPS −$0.46
• Quarter ended Jun 30, 2023: revenue $126M (down 10.5% year over year), net income −$57.4M, EPS −$0.54
• Quarter ended Mar 31, 2023: revenue $122M (down 11.2% year over year), net income −$53.1M, EPS −$0.50
• Quarter ended Dec 31, 2022: revenue $128M (down 3.6% year over year), net income −$37.3M, EPS −$0.36
• Quarter ended Sep 30, 2022: revenue $131M (down 2.0% year over year), net income −$26.6M, EPS −$0.25
• Quarter ended Jun 30, 2022: revenue $141M (up 5.5% year over year), net income −$24.0M, EPS −$0.23
• Quarter ended Mar 31, 2022: revenue $138M (up 2.1% year over year), net income −$4.65M, EPS −$0.04
• Quarter ended Dec 31, 2021: revenue $133M, net income −$26.5M, EPS −$0.25
• Quarter ended Sep 30, 2021: revenue $134M, net income −$13.1M, EPS −$0.13

NVCR cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$49.0M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$26.4M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$73.3M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $30.8M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow $82.8M, share buybacks n/a

NVCR balance sheet

• Jun 30, 2026: cash $93.7M, total assets $795M, total liabilities $457M, shareholders' equity $338M
• Mar 31, 2026: cash $87.5M, total assets $788M, total liabilities $457M, shareholders' equity $331M
• Dec 31, 2025: cash $93.5M, total assets $804M, total liabilities $464M, shareholders' equity $340M, long-term debt $195M
• Sep 30, 2025: cash $342M, total assets $1.36B, total liabilities $1.02B, shareholders' equity $341M
• Jun 30, 2025: cash $150M, total assets $1.25B, total liabilities $896M, shareholders' equity $349M
• Mar 31, 2025: cash $127M, total assets $1.25B, total liabilities $887M, shareholders' equity $362M
• Dec 31, 2024: cash $164M, total assets $1.24B, total liabilities $881M, shareholders' equity $360M, long-term debt $97.3M
• Sep 30, 2024: cash $185M, total assets $1.22B, total liabilities $861M, shareholders' equity $361M

What is NVCR's revenue?

NOVOCURE LTD reported $699M of revenue over its last four quarters, through June 30, 2026.

Is NVCR profitable?

No. NOVOCURE LTD lost $149M over the last four quarters.

What is NVCR's EPS?

Diluted earnings per share over the last four quarters were −$1.30; −$0.13 in the latest quarter.

NVCR ownership and insider trades · All stocks